Cyanidin-3-glucoside enhances mitochondrial function and biogenesis in a human hepatocyte cell line
Tóm tắt
Mitochondrial dysfunction has been identified as one of the primary factors contributing to liver diseases. Pathways that control mitochondrial biogenesis are potential therapeutic targets for the amelioration of hepatocyte dysfunction and liver disease. Research on natural pharmacological agents that ameliorate liver diseases has intensified over the last two decades. Cyanidin-3-glucoside (Cy3g), a dietary flavonoid compound extracted from a wide variety of fruits and vegetables, reportedly has several beneficial health effects. In this study, we used an adult human hepatoma cell line (HuH7) to investigate the effects of the Cy3g polyphenolic compound on mitochondrial function and biogenesis in vitro. An increase in intracellular mitochondrial reductase levels was observed after treatment with Cy3g, but cytotoxicity was not induced. In addition, mitochondrial membrane potential and ATP production were increased following Cy3g treatment. Cy3g treatment also resulted in a dose- and time-dependent upregulation of the gene expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a transcription factor considered a master regulator of mitochondrial biogenesis and metabolism. Additionally, the expression of sirtuin 1 (SIRT1), which plays a key role in deacetylating PGC-1α, was also increased in a dose- and time-dependent manner. Cy3g treatment also increased the expression of downstream PGC-1α genes, nuclear respiratory factor 1 and mitochondrial transcription factor A (TFAM). Our results suggest that Cy3g has potential as a hepatoprotective therapeutic agent that enhances mitochondrial function and biogenesis in hepatocytes.
Tài liệu tham khảo
Aharoni-Simon M, Hann-Obercyger M, Pen S, Madar Z, Tirosh O (2011) Fatty liver is associated with impaired activity of PPARγ-coactivator 1α (PGC1α) and mitochondrial biogenesis in mice. Lab Invest 91:1018–1028. https://doi.org/10.1038/labinvest.2011.55
Ajmo JM, Liang X, Rogers CQ, Pennock B, You M (2008) Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 295:G833–G842. https://doi.org/10.1152/ajpgi.90358.2008
Bagchi D, Preuss HG, Swaroop A (2015) Nutraceuticals and functional foods in human health and disease prevention. CRC Press, Boca Raton, FL
Baur JA, Pearson KJ, Price NL et al (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342. https://doi.org/10.1038/nature05354
Begriche K, Igoudjil A, Pessayre D, Fromenty B (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6:1–28. https://doi.org/10.1016/j.mito.2005.10.004
Brand MD, Nicholls DG (2011) Assessing mitochondrial dysfunction in cells. Biochem J 435:297–312. https://doi.org/10.1042/BJ20110162
Canto C, Auwerx J (2012) Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacol Rev 64:166–187. https://doi.org/10.1124/pr.110.003905
Cantó C, Auwerx J (2009) PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20:98–105. https://doi.org/10.1097/MOL.0b013e328328d0a4
Cassidy A, Mukamal KJ, Liu L, Franz M, Eliassen AH, Rimm EB (2013) High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged womenclinical perspective. Circulation 127:188–196. https://doi.org/10.1161/CIRCULATIONAHA.112.122408
Chavez-Tapia NC, Rosso N, Tiribelli C (2012) Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol 12:20. https://doi.org/10.1186/1471-230X-12-20
Chow J, Rahman J, Achermann JC, Dattani MT, Rahman S (2016) Mitochondrial disease and endocrine dysfunction. Nat Rev Endocrinol 13:92–104. https://doi.org/10.1038/nrendo.2016.151
Davinelli S, Sapere N, Visentin M, Zella D, Scapagnini G (2013) Enhancement of mitochondrial biogenesis with polyphenols: combined effects of resveratrol and equol in human endothelial cells. Immun Ageing 10:28. https://doi.org/10.1186/1742-4933-10-28
Ding R-B, Bao J, Deng C-X (2017) Emerging roles of SIRT1 in fatty liver diseases. Int J Biol Sci 13:852–867. https://doi.org/10.7150/ijbs.19370
Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679–689. https://doi.org/10.1002/hep.23280
Finck BN, Kelly DP (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116:615–622. https://doi.org/10.1172/JCI27794
Guo H, Liu G, Zhong R, Wang Y, Wang D, Xia M (2012) Cyanidin-3-O-β-glucoside regulates fatty acid metabolism via an AMP-activated protein kinase-dependent signaling pathway in human HepG2 cells. Lipids Health Dis 11:10. https://doi.org/10.1186/1476-511X-11-10
Gustafsson AB, Gottlieb RA (2007) Heart mitochondria: gates of life and death. Cardiovasc Res 77:334–343. https://doi.org/10.1093/cvr/cvm005
Han H-S, Kang G, Kim JS, Choi BH, Koo S-H (2016) Regulation of glucose metabolism from a liver-centric perspective. Exp Mol Med 48:e218. https://doi.org/10.1038/emm.2015.122
Hou X, Xu S, Maitland-Toolan KA (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP- activated Protein Kinase. J Biol Chem 283:20015–20026. https://doi.org/10.1074/jbc.m802187200
Jiang X, Tang X, Zhang P, Liu G, Guo H (2014) Cyanidin-3-O-β-glucoside protects primary mouse hepatocytes against high glucose-induced apoptosis by modulating mitochondrial dysfunction and the PI3K/Akt pathway. Biochem Pharmacol 90:135–144. https://doi.org/10.1016/j.bcp.2014.04.018
Johri A, Beal MF (2012) Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther 342:619–630. https://doi.org/10.1124/jpet.112.192138
Krelle AC, Okoli AS, Mendz GL (2013) Huh-7 human liver cancer cells: a model system to understand hepatocellular carcinoma and therapy. J Cancer Ther 04:606–631. https://doi.org/10.4236/jct.2013.42078
Leone TC, Lehman JJ, Finck BN et al (2005) PGC-1α deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3:e101. https://doi.org/10.1371/journal.pbio.0030101
Li X, Wang H, Gao Y, Li L, Tang C, Wen G, Yang Y, Zhuang Z, Zhou M, Mao L, Fan Y (2016) Quercetin induces mitochondrial biogenesis in experimental traumatic brain injury via the PGC-1α signaling pathway. Am J Transl Res 8:3558–3566
Matsukawa T, Inaguma T, Han J, Villareal MO, Isoda H (2015) Cyanidin-3-glucoside derived from black soybeans ameliorate type 2 diabetes through the induction of differentiation of preadipocytes into smaller and insulin-sensitive adipocytes. J Nutr Biochem 26:860–867. https://doi.org/10.1016/j.jnutbio.2015.03.006
Matsukawa T, Motojima H, Sato Y, Takahashi S, Villareal MO, Isoda H (2017) Upregulation of skeletal muscle PGC-1α through the elevation of cyclic AMP levels by Cyanidin-3-glucoside enhances exercise performance. Sci Rep 7:44799. https://doi.org/10.1038/srep44799
Morino K, Petersen KF, Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55:S9–S15. https://doi.org/10.2337/db06-S002
Nassir F, Ibdah J (2014) Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci 15:8713–8742. https://doi.org/10.3390/ijms15058713
Nassir F, Ibdah JA (2016) Sirtuins and nonalcoholic fatty liver disease. World J Gastroenterol 22:10084–10092. https://doi.org/10.3748/wjg.v22.i46.10084
Nikolić N, Rhedin M, Rustan AC, Storlien L, Thoresen GH, Strömstedt M (2012) Overexpression of PGC-1α increases fatty acid oxidative capacity of human skeletal muscle cells. Biochem Res Int 2012:714074. https://doi.org/10.1155/2012/714074
Nunnari J, Suomalainen A (2012) Mitochondria: in sickness and in health. Cell 148:1145–1159. https://doi.org/10.1016/j.cell.2012.02.035
Pessayre D, Mansouri A, Fromenty B (2002) V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 282:G193–G199. https://doi.org/10.1152/ajpgi.00426.2001
Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140–1142. https://doi.org/10.1126/science.1082889
Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X (2009) Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metabol 9:327–338. https://doi.org/10.1016/j.cmet.2009.02.006
Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ, Mikus CR, Laye MJ, Laughlin MH, Booth FW, Ibdah JA (2010) Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol 52:727–736. https://doi.org/10.1016/j.jhep.2009.11.030
Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434:113–118. https://doi.org/10.1038/nature03354
Sakamuru S, Attene-Ramos MS, Xia M (2016) Mitochondrial membrane potential assay. Methods Mol Biol 1473:17–22. https://doi.org/10.1007/978-1-4939-6346-1_2
Scarpulla RC (2011) Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta 1813:1269–1278. https://doi.org/10.1016/j.bbamcr.2010.09.019
Song S, Attia RR, Connaughton S, Niesen MI, Ness GC, Elam MB, Hori RT, Cook GA, Park EA (2010) Peroxisome proliferator activated receptor α (PPARα) and PPAR gamma coactivator (PGC-1α) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements. Mol Cell Endocrinol 325:54–63. https://doi.org/10.1016/j.mce.2010.05.019
Tan M, Tang C, Zhang Y (2015) SIRT1/PGC-1α signaling protects hepatocytes against mitochondrial oxidative stress induced by bile acids. Free Radical Res 49:935–945. https://doi.org/10.3109/10715762.2015.1016020
Vega RB, Huss JM, Kelly DP (2000) The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 20:1868–1876. https://doi.org/10.1128/MCB.20.5.1868-1876.2000
Ventura-Clapier R, Garnier A, Veksler V (2008) Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res 79:208–217. https://doi.org/10.1093/cvr/cvn098
Wallace DC (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 39:359–407. https://doi.org/10.1146/annurev.genet.39.110304.095751
Wang RH, Li C, Deng CX (2010) Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition. Int J Biol Sci 6:682–690. https://doi.org/10.7150/ijbs.6.682
Watson RR, Preedy VR, Zibadi S (2013) Polyphenols in human health and disease. Elsevier Science, London
Wei X, Wang D, Yang Y et al (2011) Cyanidin-3-O-β-glucoside improves obesity and triglyceride metabolism in KK-Ay mice by regulating lipoprotein lipase activity. J Sci Food Agric 91:1006–1013. https://doi.org/10.1002/jsfa.4275
You Y, Yuan X, Liu X et al (2017) Cyanidin-3-glucoside increases whole body energy metabolism by upregulating brown adipose tissue mitochondrial function. Mol Nutr Food Res 61(11). https://doi.org/10.1002/mnfr.201700261